Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
Abstract Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes in tumour-i...
Main Authors: | G. Griguolo, G. Serna, T. Pascual, R. Fasani, X. Guardia, N. Chic, L. Paré, S. Pernas, M. Muñoz, M. Oliveira, M. Vidal, A. Llombart-Cussac, J. Cortés, P. Galván, B. Bermejo, N. Martínez, R. López, S. Morales, I. Garau, L. Manso, J. Alarcón, E. Martínez, P. Villagrasa, A. Prat, P. Nuciforo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-03-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-021-00163-6 |
Similar Items
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
by: Tomás Pascual, et al.
Published: (2021-11-01) -
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
by: Francesco Schettini, et al.
Published: (2021-01-01) -
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
by: Leticia De Mattos-Arruda, et al.
Published: (2021-06-01) -
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
by: Francesco Schettini, et al.
Published: (2023-04-01) -
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
by: Gaia Griguolo, et al.
Published: (2020-07-01)